{"prompt": "['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', 'Table 1: Study Flow-Chart for head & neck cancer subjects', 'RT &', '2 weeks', 'RT', 'Phase of the study', 'Screening', 'treatment', 'RT (expected 33-35 sessions)', 'treatment', 'end', 'start', 'without RT', 'Visit number', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'Week', '-', '0', '1', '2', '3', '4', '5', '6', '7', '9', 'Time (Days) 2 days', '-3 to 0', '1', '7', '14', '21', '28', '35', '42', '49', '63', 'Informed consent signature', 'X', 'Inclusion/Exclusion criteria', 'X', 'X', 'Patient randomization', 'X', 'Socio-demographic data', 'X', 'Medical and surgical history', 'X', 'collection', 'Physical examination', 'X', 'X', 'X', 'Concomitant medications and', 'X', 'X', 'X', 'therapies', 'ECOG performance status', 'X', 'Erythema assessment', 'X', 'X', 'X', 'Skindex-16 questionnaire', 'X', 'X', 'X', 'Spettrophotometry & TEWL', 'X', 'X', 'Study treatment dispensation to', 'X', 'patient', 'Study treatment return and', 'X', 'accountability', 'Patient diary dispensation', 'X', 'Patient diary collection', 'X', 'Patient Global Satisfaction score', 'X', 'X', 'Adverse events', 'X', 'X', 'CONFIDENTIAL', 'Page 11 of 53']['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', 'Table 2: Study Flow-Chart for breast cancer subjects', 'RT &', '2 weeks', 'RT', 'Phase of the study', 'Screening', 'treatment', 'RT (expected 30 sessions)', 'treatment', 'end', 'start', 'without RT', 'Visit number', '1', '2', '3', '4', '5', '6', '7', '8', '9', 'Week', '-', '0', '1', '2', '3', '4', '5', '6', '8', 'Time (Days) 2 days', '-3 to 0', '1', '7', '14', '21', '28', '35', '42', '56', 'Informed consent signature', 'X', 'Inclusion/Exclusion criteria', 'X', 'X', 'Patient randomization', 'X', 'Socio-demographic data', 'X', 'Medical and surgical history', 'X', 'collection', 'Physical examination', 'X', 'X', 'X', 'Concomitant medications and', 'X', 'X', 'X', 'therapies', 'ECOG performance status', 'X', 'Erythema assessment', 'X', 'X', 'X', 'Skindex-16 questionnaire', 'X', 'X', 'Spettrophotometry & TEWL', 'X', 'X', 'Study treatment dispensation to', 'X', 'patient', 'Study treatment return and', 'X', 'accountability', 'Patient diary dispensation', 'X', 'X', 'Patient diary collection', 'X', 'X', 'Patient Global Satisfaction score', 'X', 'Adverse events', 'X', 'X', 'Table 3: CTCAE v4.0 Term Dermatitis Radiation', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Life-threatening', 'consequences; skin', 'Moderate to brisk', 'Moist desquamation in', 'necrosis or ulceration of', 'erythema; patchy moist', 'areas other than skin', 'full thickness dermis;', 'desquamation, mostly', 'folds and creases;', 'spontaneous bleeding', 'Faint erythema or dry', 'confined to skin folds and', 'bleeding induced by', 'from involved site; skin', 'desquamation', 'creases; moderate edema', 'minor trauma or abrasion', 'graft indicated', 'Death', 'CONFIDENTIAL', 'Page 12 of 53']['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', '2. Identification and description of the investigational device', 'Xonrid is an EC-marked medical device class lla for radiation dermatitis; it is a topical gel that prevents', 'and treats skin symptoms such as erythema, itching, burning sensation and pruritus, induced by', 'radiotherapy or other causes.', 'When applied to the target skin areas, Xonrid forms a protective film, reduces the TEWL (Trans', 'Epidermal Water Loss) and increases moisturizing.', 'It promotes the healing process by restoring the physiological hydration levels of the affected skin areas.', 'It can be applied to the target areas including skin folds and creases, with or without minor trauma or', 'abrasions.', 'Xonrid is manufactured by Helsinn Healthcare SA.', '3. Justification for the design of the clinical investigation', 'Acute radiation dermatitis is a common side effect of radiotherapy in many forms of cancer, first of all', 'breast and head & neck. The intensity of the reaction depends on radiotherapy parameters (dose per', 'fraction, total dose, use of bolus or other beam-modifying devices, type and energy of radiation, size of', 'the treatment field and site treated) and on concomitant chemotherapy employment. Although with a', 'lesser grade, other factors involved in determining the intensity of radiation dermatitis are comorbidities', '(e.g. diabetes) and individual susceptibility12.', 'Skin reactions during radiotherapy, scored according to different systems, usually span in severity from', 'mild erythema (grade 1) to moist desquamation confined to skin folds (grade 2) or not (grade 3).', 'Large ulcerations that require surgical procedures (grade 4) with potential lethal consequences (grade', '5) are exceptional and should be considered non-acceptable complications in routine practice.', 'Early onset of severe acute skin reaction during treatment could be responsible for a reduced', 'compliance to the planned schedule of irradiation, so jeopardizing local disease control.', 'The most used scales for assessing toxicities (Radiation Therapy Oncology Group RTOG and CTCAE) do', 'not capture symptoms as reported by the patients. Moreover, adverse events assessed by physicians', 'are less accurate than patient-reported outcome (PRO) instruments and some clinicians have proposed', 'replacing physician scales with patient-assessed reporting of adverse events3-4', 'A recent trial showed how CTCAE and the PRO Skindex-16 were supplementary and that patients', 'reported a greater number of symptoms. The Skindex-16 allows patient rating of emotional and', \"functional burdens that the CTCAE does not take into account5. These adverse events cause patient's\", 'discomfort and impact negatively on quality of life6.', 'CONFIDENTIAL', 'Page 13 of 53']\n\n###\n\n", "completion": "END"}